Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer
Authors:
- 1 January 1992
- journal article
- clinical trial
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 119 (1) , 55-57
Abstract
Eighteen previously treated patients with advanced ovarian cancer were entered into a phase 2 trial of chronic low-dose oral etoposide (50 mg/day for 20 days, repeated every 28 days) to determine the activity of this therapeutic strategy in organoplatinum-refractory disease. The treatment program was generally well tolerated, with mild neutropenia the most common side-effect encountered. One patient (6%; 95% confidence interval=0–17%) achieved a partial response, which lasted for 11 months. Three additional patients (17%), who failed to meet the criteria of a partial response, demonstrated objective evidence of antineoplastic activity. Chronic low-dose oral etoposide administration is associated with definite, although modest, activity in platinumrefractory ovarian cancer.Keywords
This publication has 21 references indexed in Scilit:
- A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activityInternational Journal of Gynecological Cancer, 1992
- A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.Journal of Clinical Oncology, 1991
- A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.Journal of Clinical Oncology, 1990
- Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinomaGynecologic Oncology, 1987
- PHASE-I PHARMACOKINETIC STUDY OF INTRAPERITONEAL CISPLATIN AND ETOPOSIDE1987
- Ovarian cancerCurrent Problems in Cancer, 1987
- Cisplatin Plus VP16 213 in Refractory Ovarian CarcinomaAmerican Journal of Clinical Oncology, 1987
- Etoposide (VP‐16) plus cisplatin (DDP): A new active chemotherapeutic combination in patients with stage iii‐iv ovarian adenocarcinomaJournal of Surgical Oncology, 1986
- Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agentsGynecologic Oncology, 1978
- SCHEDULE DEPENDENCY OF THE ANTILEUKEMIC ACTIVITY OF THE PODOPHYLLOTOXIN‐DERIVATIVE VP 16–213 (NSC‐141540) IN L1210 LEUKEMIAActa Pathologica Microbiologica Scandinavica Section A Pathology, 1973